Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has secured an Australian patent for two of its anti-infective drug candidates — the first in its Patent Family 4 cohort.
The Australian patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), specifically:
- how Recce prepares its anti-infectives;
- using R327 and R529 to treat diseases and bacterial and viral infections, further validating their use in studies covering burn wounds, urinary tract infections, gonorrhoea, influenza and SARSCoV2; and
- administering the anti-infectives via oral, inhalation or transdermal delivery methods, as well as via injection or through an aerosol, gel, topical foam or ointment.
Recce CEO James Graham said: “We are thrilled to see this new family of intellectual property be granted in Australia; with further market-monopolies reinforcing opportunities among a significant range of bacterial and viral pathogens.”
Myriad bacteria and viral pathogens are covered in Recce’s Patent Family 4; a promising sign of R327 and R529’s extensive treatment opportunities.
R327 data validated
Thursday’s patent news comes just days after Recce verified some positive Phase 1 data from an R327 intravenous study.
Recently, the company conducted a randomised, placebo-controlled, first-in-human trial to evaluate how R327 performed as an intravenous infusion formulation in 80 healthy male subjects.
Since then, independent examiners have looked over data from the 80-person trial, finding all participants achieved the primary study end-points and met international regulatory data standards, indicating R327 is safe and well tolerated.
Overall, R327 was found to be well tolerated with a good safety profile across all dose groups from 50 milligrams to 6,000 milligrams when administrated intravenously over one-hour infusion.
Recce has since completed a Phase I/II UTI clinical trial ahead of schedule, evaluating R327 at faster intravenous infusion rates.
Graham explained: “R327 via two faster infusion rates of 2,500mg across male and female subjects continues to be shown as safe and well tolerated.
“Completing dosing well ahead of schedule is a welcomed confirmation that we are on track to achieving study objectives."